Form 4: Celldex Therapeutics Executive Richard M. Wright Acquires 65,000 Stock Options

Richard M. Wright, SR. VP & CCO of Celldex Therapeutics, acquired 65,000 incentive stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Summary

• Richard M. Wright, a Senior Vice President & CCO at Celldex Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 13, 2024, where Wright acquired 65,000 incentive stock options.
• These options, granted under the company's 2021 Omnibus Equity Incentive Plan, have an exercise price of $36.43.
• The options vest 25% on June 13, 2025, with the remaining portion vesting quarterly over the following 12 quarters.
• The options expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an executive stock option grant, which is a common practice. It doesn't inherently indicate positive or negative performance.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, potentially leading to increased shareholder value.

Key Dates